Sutykine 50 mg Capsule Washington | Bulk Oncology Exporter from India

Sutykine 50 mg Capsule: Targeted Multi-Kinase Inhibition for Global Oncology Excellence

Are you searching for a reliable Sutykine 50 mg Capsule exporter from India? Ernest Impex, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced oncology medications. We maintain a high-authority, cold-chain-compliant supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that critical cancer therapies reach medical institutions with 100% pharmaceutical integrity.

Detailed Product Overview: What is Sutykine 50 mg?

Sutykine 50 mg Capsule is a high-potency oral formulation containing Sunitinib, a powerful multi-targeted tyrosine kinase inhibitor (TKI). Manufactured by Intas Pharmaceuticals Ltd., Sutykine 50 mg is designed to disrupt the specific signaling pathways that malignant cells use to proliferate and survive.

For international B2B procurement, Sutykine 50 mg is a critical second-line and primary treatment option for patients with advanced solid tumors, particularly those resistant to earlier therapeutic interventions like Imatinib.

Primary Therapeutic Indications

Sutykine 50 mg is clinically utilized globally for the following:

1. Metastatic Renal Cell Carcinoma (mRCC): A primary treatment for advanced kidney cancer that has spread to other parts of the body.

2. Gastrointestinal Stromal Tumor (GIST): Specifically for patients where Imatinib therapy has failed or is clinically contraindicated.

3. Pancreatic Neuroendocrine Tumors (pNET): For well-differentiated, progressive tumors of the hormone-producing cells in the pancreas.

Mechanism of Action: Advanced Pathway Signal Inhibition

Sutykine 50 mg operates through a sophisticated "multi-target" biological approach:

• VEGF Receptor Blockade: It inhibits Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, -3), which are essential for angiogenesis (the formation of new blood vessels that "feed" the tumor).

• PDGF Receptor Inhibition: By targeting Platelet-Derived Growth Factor Receptors (PDGFR-α and -β), it disrupts the communication pathways that promote cancer cell survival and migration.

• KIT & FLT3 Targeting: It binds to the stem cell factor receptor (KIT) and Fms-like tyrosine kinase-3 (FLT3), interrupting the internal signals that drive rapid cell division in gastrointestinal and hematological malignancies.

• Tumor Starvation: This dual approach not only stops cell division but also starves the tumor of its oxygen and nutrient supply.

Administration and Clinical Safety

• Dosage Protocol: Sutykine 50 mg is usually taken once daily. For GIST and RCC, a standard 6-week cycle (4 weeks on, 2 weeks off) is often employed.

• Storage: Store at room temperature (below 30°C) in a cool, dry place, protected from direct light and moisture.

• Key Monitoring Parameters:

  • Cardiac Health: Regular monitoring for left ventricular ejection fraction (LVEF) and hypertension is essential.

  • Thyroid Function: Routine screening for hypothyroidism is standard during Sunitinib therapy.

  • Liver & Kidney Function: Periodic LFTs and KFTs are required to monitor organ health during treatment.

  • Blood Glucose: Patients should be monitored for potential hypoglycemia (low blood sugar).

Why Source Sutykine from Ernest Impex?

• Authentic Intas Oncology Exporter: Direct access to genuine Intas Pharmaceuticals inventory, ensuring 100% authenticity and competitive bulk pricing for global markets.

• Global Logistics Authority: We specialize in the complex documentation and cold-chain logistics required for Washington, London, Bangkok, Canberra, Singapore, and Kingston.

• Regulatory Transparency: We provide all essential B2B documentation, including GMP compliance, batch-specific COAs, and international export permits.

• Supply Chain Resilience: In 2026, we prioritize real-time transparency and automated replenishment for hospital groups and regional distributors.